Payment overview · 2025
General Payments
$11,995.53
80 reported records · 17 companies
Healthcare provider profile · identity verified
Jonathan Bonilla, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SEGUIN, TX · NPI 1013177013
Verified facts
What the public records show
CMS Open Payments records show Jonathan Bonilla, MD received $11,995.53 in general payments during 2025 across 80 reported records.
Penumbra, Inc. accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $3,340.22 | 27.9% | 10 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $3,119.04 | 26.0% | 9 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $1,686.26 | 14.1% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,015.39 | 8.5% | 4 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $915.48 | 7.6% | 19 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $558.76 | 4.7% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $354.48 | 3.0% | 7 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $320.54 | 2.7% | 5 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $180.74 | 1.5% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $140.29 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $123.92 | 1.0% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $59.16 | 0.5% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $51.62 | 0.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $49.40 | 0.4% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $36.60 | 0.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $25.67 | 0.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.96 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,497.57 | 71 |
| Travel and Lodging | $2,657.96 | 7 |
| Consulting Fee | $2,640.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,200.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $3,119.04 | 9 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $3,008.06 | 7 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $1,024.49 | 8 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $820.97 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $558.76 | 3 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $510.96 | 2 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $332.16 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $331.55 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $331.55 | 2 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $320.54 | 5 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $140.29 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $140.29 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $140.29 | 1 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $140.29 | 1 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $140.29 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $123.92 | 3 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $103.09 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $91.33 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $59.16 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $51.62 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $51.62 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $49.40 | 1 | 2025 |
Source payment records
|
|||||
| Atlas Normalized: atlas |
Device | Bard Peripheral Vascular, Inc. | $36.60 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $25.67 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 129 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 94 | 52 |
| Xarelto | Rivaroxaban | 91 | 34 |
| Furosemide | Furosemide | 59 | 30 |
| Eliquis | Apixaban | 51 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 39 | 27 |
| Lisinopril | Lisinopril | 33 | 15 |
| Losartan Potassium | Losartan Potassium | 29 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Cilostazol | Cilostazol | 15 | 11 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,995.53 · 80 records | Penumbra, Inc. | AURYON LASER SYSTEM 100-120 VAC, Atlas, BioMimics 3D Vascular Stent System, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, ELUVIA, ENDOCROSS Device, FFRct, FLOWTRIEVER CATHETER, S, General - Vascular Intervention, Indigo System, LEQVIO, LIMFLOW SYSTEM, Labosys, LifeVest, PROCLAIM, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, RUBY Coil, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, Torus Stent Graft System, Varithena Administration Pack | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error